ZA202407225B - Salt and crystal form of dipeptidyl peptidase inhibitor compound - Google Patents

Salt and crystal form of dipeptidyl peptidase inhibitor compound

Info

Publication number
ZA202407225B
ZA202407225B ZA2024/07225A ZA202407225A ZA202407225B ZA 202407225 B ZA202407225 B ZA 202407225B ZA 2024/07225 A ZA2024/07225 A ZA 2024/07225A ZA 202407225 A ZA202407225 A ZA 202407225A ZA 202407225 B ZA202407225 B ZA 202407225B
Authority
ZA
South Africa
Prior art keywords
salt
crystal form
inhibitor compound
dipeptidyl peptidase
peptidase inhibitor
Prior art date
Application number
ZA2024/07225A
Other languages
English (en)
Inventor
Fan Jiang
Dou Ying
Gong Zheng
ZHU Fengfei
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of ZA202407225B publication Critical patent/ZA202407225B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2024/07225A 2022-02-22 2024-09-20 Salt and crystal form of dipeptidyl peptidase inhibitor compound ZA202407225B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210160862 2022-02-22
PCT/CN2023/077409 WO2023160542A1 (zh) 2022-02-22 2023-02-21 二肽基肽酶抑制剂化合物的盐及晶型

Publications (1)

Publication Number Publication Date
ZA202407225B true ZA202407225B (en) 2025-12-17

Family

ID=87764787

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/07225A ZA202407225B (en) 2022-02-22 2024-09-20 Salt and crystal form of dipeptidyl peptidase inhibitor compound

Country Status (13)

Country Link
US (1) US20250188067A1 (cg-RX-API-DMAC7.html)
EP (1) EP4484414A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508792A (cg-RX-API-DMAC7.html)
KR (1) KR20240153351A (cg-RX-API-DMAC7.html)
CN (1) CN118660873A (cg-RX-API-DMAC7.html)
AU (1) AU2023225835A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002490A1 (cg-RX-API-DMAC7.html)
IL (1) IL314852A (cg-RX-API-DMAC7.html)
MX (1) MX2024010180A (cg-RX-API-DMAC7.html)
TW (1) TW202342466A (cg-RX-API-DMAC7.html)
WO (1) WO2023160542A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202407225B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506307A (ja) * 2022-02-22 2025-03-07 ハイスコ ファーマスーティカル プライベート リミテッド 含窒素複素環化合物の調製方法
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性dpp1阻害剤及びその用途
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
NO2699580T3 (cg-RX-API-DMAC7.html) * 2014-01-24 2018-02-24
PL4129989T3 (pl) * 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1,4-氧杂氮杂环庚烷的并环类衍生物

Also Published As

Publication number Publication date
EP4484414A1 (en) 2025-01-01
TW202342466A (zh) 2023-11-01
IL314852A (en) 2024-10-01
AU2023225835A1 (en) 2024-10-03
CL2024002490A1 (es) 2024-12-13
MX2024010180A (es) 2024-08-27
KR20240153351A (ko) 2024-10-22
CA3243683A1 (en) 2025-01-22
JP2025508792A (ja) 2025-04-10
US20250188067A1 (en) 2025-06-12
WO2023160542A1 (zh) 2023-08-31
EP4484414A4 (en) 2026-01-28
CN118660873A (zh) 2024-09-17

Similar Documents

Publication Publication Date Title
PH12022553603A1 (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
EP4643882A3 (en) Capsid inhibitors for the prevention of hiv
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX2024010180A (es) Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa.
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
MX2025000291A (es) Compuesto heterocíclico capaz de inhibir prmt5•mta y uso del mismo
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MX2021011823A (es) Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
AP1780A (en) Use of cox-2 inhibitors for preventing immunodeficiency.
TW200626553A (en) Novel compounds
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
MX2024015733A (es) Compuestos para el tratamiento de una infeccion por coronavirus
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2026000228A (es) Inhibidor de kat6
MXPA05010020A (es) Derivados de oxamida.